For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson Tyrosine Kinases (c-Abl kinases), announces it has ...

Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

Discover expert dog health guides covering nutrition, exercise, common conditions, preventive care, and mental wellness.

After up to three years on GA Depot, most people with PPMS have not experienced any disability progression, according to new ...

A collaborative team of researchers and students from Wayne State University's Eugene Applebaum College of Pharmacy and ...

Tecvayli monotherapy significantly reduces disease progression and mortality in relapsed or refractory multiple myeloma patients, showing a 71% reduction in progression risk and 40% in mortality risk.

DNA is often described as the instruction manual for building the fundamental components of life. Proteins are helpers that ...